Log In
BCIQ
Print this Print this
 

ESN282

  Manage Alerts
Collapse Summary General Information
Company Ogeda S.A.
Description 
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationInflammatory bowel disease (IBD)
Indication DetailsTreat ulcerative colitis (UC)
Regulatory Designation
PartnerMerck & Co. Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today